Literature DB >> 27007612

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.

Isha Saini1, Mani Kalaivani2, Sushil Kumar Kabra3.   

Abstract

The aim was to retrospectively estimate the prevalence of calcinosis in patients with juvenile dermatomyositis (JDM) and to identify risk factors associated with development of calcinosis in these patients. Retrospective chart review of 39 children diagnosed with JDM between 2004 and 2015 in a tertiary care hospital was done. Patients were divided into two groups, depending on the presence or absence of calcinosis, and the two groups were compared with respect to demographic, clinical, laboratory and therapeutic characteristics. Calcinosis developed in nine (23.1 %) patients. Delay in diagnosis and initiation of treatment, prolonged duration of disease, the presence of joint contractures and cardiac involvement were significantly associated with increased frequency of calcinosis. Six out of nine (66.7 %) patients with calcinosis received alendronate therapy, out of which four showed partial reduction in calcinosis. In one case, surgical removal of tumorous clumps was done. Calcinosis remains a common complication of JDM. We found an association between calcinosis and delay in diagnosis and initiation of treatment, prolonged duration of disease and cardiac involvement. Our study suggests that alendronate may be beneficial in management of calcinosis of JDM.

Entities:  

Keywords:  Alendronate; Calcinosis; Juvenile dermatomyositis; Risk factors

Mesh:

Substances:

Year:  2016        PMID: 27007612     DOI: 10.1007/s00296-016-3467-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis.

Authors:  Petros Efthimiou; Manil Kukar; Lawrence J Kagen
Journal:  J Rheumatol       Date:  2010-01       Impact factor: 4.666

3.  Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.

Authors:  A Marco Puche; I Calvo Penades; B Lopez Montesinos
Journal:  Clin Exp Rheumatol       Date:  2010 Jan-Feb       Impact factor: 4.473

4.  Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Authors:  Antonia Valenzuela; Lorinda Chung; Livia Casciola-Rosen; David Fiorentino
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

5.  Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.

Authors:  Angelo Ravelli; Lucia Trail; Cristina Ferrari; Nicolino Ruperto; Angela Pistorio; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Matilde Beltramelli; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Silvia Magni-Manzoni; Eunice Solis-Valleoj; Marcia Bandeira; Francesco Zulian; Vicente Baca; Elisabetta Cortis; Fernanda Falcini; Maria Alessio; Maria Giannina Alpigiani; Valeria Gerloni; Claudia Saad-Magalhaes; Rosanna Podda; Clovis A Silva; Loredana Lepore; Enrico Felici; Federica Rossi; Elena Sala; Alberto Martini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-01-15       Impact factor: 4.794

6.  Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

Authors:  S P Luckman; F P Coxon; F H Ebetino; R G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

7.  Juvenile dermatomyositis and polymyositis.

Authors:  L M Pachman; M C Maryjowski
Journal:  Clin Rheum Dis       Date:  1984-04

8.  Anticalcification and antiresorption effects of bisacylphosphonates.

Authors:  J M Van Gelder; E Breuer; A Ornoy; A Schlossman; N Patlas; G Golomb
Journal:  Bone       Date:  1995-05       Impact factor: 4.398

Review 9.  Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes.

Authors:  A V Ramanan; Brian M Feldman
Journal:  Rheum Dis Clin North Am       Date:  2002-11       Impact factor: 2.670

10.  Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.

Authors:  Dinara Guseinova; Alessandro Consolaro; Lucia Trail; Cristina Ferrari; Angela Pistorio; Nicolino Ruperto; Antonella Buoncompagni; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Eunice Solis-Vallejo; Marcia Bandeira; Vicente Baca; Claudia Saad-Magalhaes; Clovis A Silva; Roberto Barcellona; Luciana Breda; Rolando Cimaz; Romina Gallizzi; Rosaria Garozzo; Silvana Martino; Antonella Meini; Achille Stabile; Alberto Martini; Angelo Ravelli
Journal:  Clin Exp Rheumatol       Date:  2011-02-23       Impact factor: 4.473

View more
  7 in total

Review 1.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

2.  Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children.

Authors:  Sulaiman M Al-Mayouf; Nora AlMutiari; Mohammed Muzaffer; Rawiah Shehata; Adel Al-Wahadneh; Reem Abdwani; Safia Al-Abrawi; Mohammed Abu-Shukair; Zeyad El-Habahbeh; Abdullah Alsonbul
Journal:  Rheumatol Int       Date:  2017-07-06       Impact factor: 2.631

3.  Juvenile dermatomyositis: a tertiary center experience.

Authors:  Kenan Barut; Pinar Ozge Avar Aydin; Amra Adrovic; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

Review 4.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

5.  Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.

Authors:  Natasa Toplak; Pallavi Pimpale Chavan; Silvia Rosina; Tomas Dallos; Oz Rotem Semo; Cassyanne L Aguiar; Raju Khubchandani; Angelo Ravelli; Anjali Patwardhan
Journal:  Front Pediatr       Date:  2022-02-23       Impact factor: 3.418

Review 6.  Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?

Authors:  Esther Guadalupe Corona-Sanchez; Erika Aurora Martínez-García; Andrea Verónica Lujano-Benítez; Oscar Pizano-Martinez; Ivette Alejandra Guerra-Durán; Efrain Chavarria-Avila; Andrea Aguilar-Vazquez; Beatriz Teresita Martín-Márquez; Kevin Javier Arellano-Arteaga; Juan Armendariz-Borunda; Felipe Perez-Vazquez; Ignacio García-De la Torre; Arcelia Llamas-García; Brenda Lucía Palacios-Zárate; Guillermo Toriz-González; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

7.  Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.

Authors:  Amir B Orandi; Vikas R Dharnidharka; Noor Al-Hammadi; Kevin W Baszis
Journal:  Pediatr Rheumatol Online J       Date:  2018-12-29       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.